Suppr超能文献

感染 BA.5 后,针对 XBB 奥密克戎亚变种的中和抗体水平较低。

Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection.

机构信息

Laboratory of Aging Research and Cancer Drug Target, Department of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China.

NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing, 102206, China.

出版信息

Signal Transduct Target Ther. 2023 Jun 19;8(1):252. doi: 10.1038/s41392-023-01495-4.

Abstract

The COVID-19 response strategies in Chinese mainland were recently adjusted due to the reduced pathogenicity and enhanced infectivity of Omicron subvariants. In Chengdu, China, an infection wave was predominantly induced by the BA.5 subvariant. It is crucial to determine whether the hybrid anti-SARS-CoV-2 immunity following BA.5 infection, coupled with a variety of immune background, is sufficient to shape the immune responses against newly emerged Omicron subvariants, especially for XBB lineages. To investigate this, we collected serum and nasal swab samples from 108 participants who had been infected in this BA.5 infection wave, and evaluated the neutralization against pseudoviruses. Our results showed that convalescent sera from individuals, regardless of vaccination history, had remarkably compromised neutralization capacities against the newly emerged XBB and XBB.1.5 subvariants. Although post-vaccination with BA.5 breakthrough infection slightly elevated plasma neutralizing antibodies against a part of pseudoviruses, the neutralization activities were remarkably impaired by XBB lineages. Furthermore, we analyzed the impacts of the number of vaccinations, age, and sex on the humoral and cellular immune response after BA.5 infection. Our findings suggest that the neutralization against XBB lineages that elicited by current hybrid immunity after BA.5 infection, are remained at low levels, indicating an urgent need for the development of next-generation of COVID-19 vaccines that designed based on the XBB sub-lineages and other future variants.

摘要

由于奥密克戎亚变种的致病性降低和感染力增强,中国大陆最近调整了 COVID-19 应对策略。在中国成都,由 BA.5 亚变种引发了一波感染。重要的是要确定 BA.5 感染后产生的混合抗 SARS-CoV-2 免疫,加上各种免疫背景,是否足以塑造对新出现的奥密克戎亚变种的免疫反应,特别是对 XBB 谱系。为了研究这一点,我们从 108 名在此次 BA.5 感染浪潮中感染的参与者中收集了血清和鼻腔拭子样本,并评估了对假病毒的中和作用。我们的结果表明,无论接种史如何,个体的恢复期血清对新出现的 XBB 和 XBB.1.5 亚变种的中和能力明显下降。尽管 BA.5 突破性感染后的疫苗接种后略微提高了对部分假病毒的血浆中和抗体,但 XBB 谱系显著损害了中和活性。此外,我们分析了接种次数、年龄和性别对 BA.5 感染后体液和细胞免疫反应的影响。我们的研究结果表明,由当前 BA.5 感染后混合免疫引起的针对 XBB 谱系的中和作用仍然处于低水平,这表明迫切需要开发基于 XBB 亚谱系和其他未来变体的下一代 COVID-19 疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a05/10279763/08b02cf89529/41392_2023_1495_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验